EXAS
Exact Sciences CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
8.29
P/S
6.17
EV/EBITDA
506.73
DCF Value
$75.91
FCF Yield
1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.7%
Operating Margin
-6.2%
Net Margin
-6.4%
ROE
-8.5%
ROA
-8.1%
ROIC
-4.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $878.4M | $-86.0M | $-0.45 |
| FY 2025 | $3.25B | $-207.9M | $-1.10 |
| Q3 2025 | $850.7M | $-19.6M | $-0.10 |
| Q2 2025 | $811.1M | $-1.2M | $-0.01 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.44
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.